Follistatin-344: What It Is and What Research Shows

The 344 in Follistatin-344 is not a strength, a batch code, or a concentration in milligrams. It is an amino acid count, and it refers to a precursor protein that never circulates in that form in a living organism. Once the 29-residue signal peptide is cleaved during secretion, what the cell actually releases is a 315-residue mature protein. Nearly every misunderstanding about this compound traces back to that one structural fact.

Our team fields identity and verification questions from laboratory buyers constantly, and few research proteins get mislabelled as often as this one. The pattern is consistent: a vial arrives, the certificate of analysis reports a mass that doesn't match what the buyer expected, and nobody can explain why.

What is Follistatin-344?

Follistatin-344 is the full-length 344-amino-acid precursor form of human follistatin, a secreted cysteine-rich glycoprotein that binds and neutralises TGF-beta superfamily ligands including activin A and myostatin (GDF-8). After signal peptide cleavage it yields the circulating FS-315 isoform. It is a research-use-only material with no approved human application.

The common oversimplification is that Follistatin-344 is simply a myostatin inhibitor. It does bind myostatin, but myostatin is one ligand among many. Follistatin also neutralises activin A, activin B, GDF-11, and several bone morphogenetic proteins, which is why the biology reaches far beyond skeletal muscle (Int J Biochem Cell Biol, 1998). This page covers molecular identity and isoform structure, what the peer-reviewed literature does and does not report, what is known about clearance, how laboratories verify a vial, and how the compound sits against related research materials.

What is Follistatin-344 and where does the name come from?

The name is a sequence length, not a potency grade. Follistatin-344 refers to the protein encoded by the FST344 splice variant of the FST gene, located on human chromosome 5q11.2. The FST gene produces two primary transcripts through alternative splicing: FST344, which encodes the 344-residue precursor, and FST317, which encodes a shorter precursor.

After co-translational removal of the 29-amino-acid N-terminal signal peptide, FST344 yields FS-315, the long isoform that circulates in serum with relatively low affinity for cell-surface heparan sulfate proteoglycans. FST317 yields FS-288, a short isoform that binds heparan sulfate avidly and therefore stays tethered to cell surfaces and basement membranes rather than travelling through the bloodstream. A third form, FS-303, arises from proteolytic processing in gonadal tissue.

Structurally, follistatin is built from an N-terminal domain followed by three cysteine-rich follistatin domains, each containing EGF-like and kazal-like motifs. The classic biochemical review describing this architecture and the protein's ligand-binding behaviour remains a useful starting point (Int J Biochem Cell Biol, 1998). Glycosylation pushes the apparent mass of secreted forms to roughly 35 to 40 kilodaltons on a gel, which is why an unglycosylated bacterially expressed preparation runs noticeably lower.

If you want the plain-language version of the isoform question, our introduction to the compound and our breakdown of whether follistatin and Follistatin-344 are the same thing both go deeper on naming conventions.

How does the molecule work at the receptor level?

Follistatin works by sequestration, not by receptor antagonism. It does not sit on a receptor and block it. Instead, two follistatin monomers wrap around a single activin or myostatin dimer in a near-complete encirclement, physically occluding the binding surfaces the ligand would otherwise use to engage both its type II receptor (ActRIIA or ActRIIB) and its type I receptor (ALK4 or ALK5).

With myostatin neutralised, the downstream consequence is loss of Smad2/Smad3 phosphorylation in muscle tissue. Smad2/3 signalling normally suppresses the Akt/mTOR axis and drives transcription of atrophy-associated ubiquitin ligases. Remove that brake and protein synthesis signalling is de-repressed. This is the mechanistic basis for treating skeletal muscle as a secretory tissue that both produces and responds to myokines (J Pharmacol Sci, 2014).

Here is the part that matters for interpreting data: because follistatin binds activin A roughly as well as it binds myostatin, any experimental system using it as a myostatin tool is also inhibiting activin signalling in the pituitary, gonads, vasculature, and haematopoietic compartment. That is a feature in some study designs and a confounder in others.

Our team has worked with researchers who assumed myostatin specificity and then struggled to explain off-target endpoints. The mechanism-focused explainer and the myostatin inhibition research guide cover the ligand-promiscuity problem in more detail.

What does the published research actually show?

The honest summary: the human literature on follistatin is overwhelmingly observational biomarker work, and the muscle-growth results people cite are almost always gene therapy studies, not studies of an administered protein.

On the biomarker side, serum myostatin and follistatin have been evaluated as monitoring and prognostic markers in dysferlinopathy (Neuromuscul Disord, 2023) and measured in patients with dermatomyositis and polymyositis (J Clin Rheumatol, 2022). Activin signalling components have been profiled in serum and pulmonary tissue in pulmonary arterial hypertension (Circulation, 2023).

Interventional human work measures endogenous follistatin, not exogenous protein. A randomised controlled trial combining resistance exercise with essential amino acid intake in older women reported an improved follistatin/myostatin ratio alongside muscle fitness measures (J Int Soc Sports Nutr, 2026). A separate 12-week randomised, double-blind, placebo-controlled trial of a pasteurised Akkermansia muciniphila preparation reported improvements in muscle strength and function (Nutrients, 2024).

Preclinical work is where the follistatin-specific causality lives. Deleting follistatin specifically from fibro-adipogenic progenitors impaired muscle function and accelerated atrophy in obese mice (Mol Med, 2025), and single-nucleus resolution work has mapped a molecular pathway for cancer cachexia-induced muscle atrophy (Cell Rep, 2024).

The thing most write-ups get wrong: the dramatic hypertrophy figures circulating online come from viral-vector studies that deliver the FS-344 transgene so tissue manufactures the protein continuously in situ. That is a fundamentally different exposure model from administering a recombinant protein, and advances in nucleic acid delivery vehicles are an active field in their own right (Cell, 2024). Attributing gene therapy outcomes to a lyophilised vial is a category error. Our gene therapy research overview, the broader literature review, the body composition research summary, the sarcopenia research page, and our assessment of anecdotal before-and-after claims all sit on this distinction.

What do studies report about side effects and unknowns?

The published safety picture for Follistatin-344 as an administered protein is essentially blank, and that absence is itself the most important finding. There is no body of controlled human safety data to summarise. What the literature does provide is a map of where broad TGF-beta superfamily interference could plausibly cause trouble.

Activin signalling is not confined to muscle. Altered activin system expression has been documented in pulmonary vascular disease (Circulation, 2023), and reviews of lean mass preservation during weight loss explicitly flag bone and haematopoietic health as tissues affected by the same signalling axis (Metabolism, 2024). Activin B also participates in hepcidin regulation and inflammation, and activin A is a canonical regulator of pituitary FSH secretion.

A second unknown is immunogenicity. Any recombinant human protein introduced into a non-human model system carries the possibility of anti-drug antibody formation, which can neutralise activity partway through a study and quietly ruin a dataset. Expression system matters here: a bacterially produced preparation lacks the glycosylation pattern of a mammalian-expressed one, and that difference can alter both clearance and immune recognition.

A third is the confusion between follistatin and follistatin-like 1 (FSTL1), a related but genuinely distinct secreted protein with its own biology, described in muscle-liver crosstalk in nonalcoholic steatohepatitis (Nat Commun, 2023). They are not interchangeable. Our long-term side effect research page catalogues the open questions in more depth.

What is known about half-life and clearance?

Clearance of follistatin is isoform-dependent, and that is the single most useful pharmacokinetic fact available. The literature describes the heparin-binding FS-288 short isoform as being rapidly removed from circulation through cell-surface proteoglycan binding and subsequent internalisation, while the longer FS-315 form derived from Follistatin-344 has markedly weaker heparan sulfate affinity and therefore persists in serum comparatively longer.

That said, published half-life figures for recombinant follistatin preparations vary considerably across species, expression system, and glycosylation state, and we are not going to quote a number we cannot anchor to a verifiable source. The research-relevant framing is that follistatin is a clearance-limited molecule with a short serum residence time relative to engineered Fc-fusion or antibody-based activin pathway tools, which is precisely why so much of the field moved toward gene delivery and fusion constructs in the first place.

For study design, three variables dominate: glycosylation state, whether the preparation is the long or short isoform, and whether carrier protein is present in the formulation. Change any one and the measured exposure curve changes with it.

In our experience supporting laboratory buyers, half-life is the question most frequently asked and least frequently answerable with a single figure. Our pharmacokinetics and research dynamics page sets out what the published range actually looks like, and our page on experimental timelines explains why onset in a model system is governed by signalling kinetics rather than serum persistence alone.

How do researchers verify a vial before it enters a study?

Verification rests on three independent documents, and a supplier that cannot produce all three should not be used for anything that will be published. The first is reversed-phase HPLC purity, which separates the target protein from truncated sequences, aggregates, and process-related impurities, and reports purity as a percentage of integrated peak area.

The second is mass spectrometry identity, typically ESI-MS or MALDI-TOF. This is where the isoform question becomes concrete: the observed mass tells you whether you received a precursor-length construct, a mature-length construct, or something glycosylated by a mammalian expression system. A mass that sits well above the calculated polypeptide mass usually means glycosylation, not contamination, but it needs to be explained rather than assumed.

The third is lot-level traceability. The lot number on the vial label must match the lot number on the certificate, and the certificate must name the expression system, the analytical methods used, and the date of analysis. Endotoxin testing is a reasonable additional requirement for any preparation entering a cell culture or in vivo model.

Our team's position is blunt: an undated certificate with no lot number is a marketing document, not an analytical one. We publish third-party certificates of analysis for our catalogue compounds for exactly this reason, and our guide to reading a Follistatin-344 certificate walks through each field line by line.

What does laboratory storage and handling involve?

Lyophilised recombinant proteins in this class are handled as cold-chain materials. Published handling practice for follistatin preparations generally calls for storage of the lyophilised powder at minus 20 degrees Celsius or lower, with minus 80 degrees Celsius preferred for long-term retention, and protection from moisture and light.

The failure mode that ruins more preparations than any other is repeated freeze-thaw cycling. Each cycle promotes partial unfolding and aggregation, and aggregated protein loses ligand-binding capacity without necessarily changing appearance. Laboratories handle this by aliquoting into single-use volumes at the point of first preparation rather than returning a working stock to the freezer repeatedly. Carrier protein such as bovine serum albumin is sometimes included in laboratory solutions to reduce surface adsorption losses at low concentrations, though it must be compatible with downstream assays.

Temperature excursions are the quiet problem. A protein that spent 36 hours at ambient temperature in transit may look identical and perform at a fraction of expected activity, which is why shipment condition should be logged alongside lot number.

Real Peptides does not publish preparation or handling-for-use instructions for any compound, because these are research-use-only materials. What we can do is explain the concentration framework researchers work within, expressed as milligrams per millilitre and read directly off the vial contents stated on the certificate. Our storage and stability guide and our concentration math reference cover the arithmetic without crossing into anything resembling use guidance.

What is the legal and research-use-only status?

Follistatin-344 has not been approved by the FDA or any comparable regulatory authority for any human or veterinary indication. It is not a drug product, not a dietary supplement, and not a compounded medication. It exists in commerce as a laboratory reagent.

Two regulatory facts are worth knowing. First, agents that interfere with myostatin and activin receptor signalling appear on the World Anti-Doping Agency Prohibited List, meaning possession and use carry consequences in sanctioned athletic contexts entirely separate from pharmaceutical regulation. Second, research-use-only labelling is a legal status with teeth: marketing such a material with human-use claims converts it into an unapproved new drug in the eyes of regulators.

All compounds discussed on this page are sold for research use only and are not for human consumption.

To be direct about our own position: Real Peptides does not carry Follistatin-344. We publish this page as a reference resource because researchers evaluating the compound ask us about it constantly, and the available information online is unusually poor. Our catalogue covers other research peptides with published literature behind them, and laboratories evaluating us as a supplier can review our supplier information and our regulatory status explainer for the fuller picture.

How does Follistatin-344 compare with related research compounds?

Researchers evaluating muscle and growth axis tools frequently shortlist these four together, which is a mistake because they operate through entirely unrelated mechanisms. The table shows molecule class, primary molecular target, and the maturity of the published evidence base.

Side-by-side breakdowns are available for Follistatin-344 versus MK-677, versus IGF-1 LR3, and versus Sermorelin, plus a wider survey of alternative research compounds.

What are the key takeaways?

• Follistatin-344 is named for a 344-amino-acid precursor; after removal of the 29-residue signal peptide, the secreted product is the 315-residue FS-315 isoform.
• Follistatin neutralises ligands by physical encirclement rather than receptor antagonism, and it binds activin A, activin B, GDF-11, and bone morphogenetic proteins in addition to myostatin.
• The dramatic muscle hypertrophy figures associated with follistatin in popular write-ups come from viral-vector gene delivery of the FS-344 transgene, not from administration of recombinant protein.
• Human follistatin data is predominantly observational biomarker work in conditions including dysferlinopathy, inflammatory myopathies, and pulmonary arterial hypertension.
• Clearance is isoform-dependent: the heparin-binding FS-288 short form is removed from circulation faster than the FS-315 long form derived from Follistatin-344.
• Verification of any vial requires three things together: RP-HPLC purity, mass spectrometry identity, and a dated certificate with a lot number matching the label.

What if: how do procurement and verification scenarios play out?

What if the vial label says Follistatin 344 but the certificate reports a mass near 38 kDa?

Check the stated expression system before concluding anything is wrong. The calculated polypeptide mass of the mature follistatin chain sits below the apparent mass observed for mammalian-expressed material because N-linked glycosylation adds considerable weight. A bacterially expressed preparation will run lower and will lack that modification entirely, which has downstream consequences for clearance and immune recognition in any model system.

What if a supplier cannot name the expression system at all?

Treat that as a disqualifying gap rather than an administrative oversight. Expression system determines glycosylation, endotoxin risk, folding fidelity, and disulfide bond formation across the cysteine-rich follistatin domains. A supplier who cannot answer the question either does not know what they are reselling or is not willing to say, and neither is acceptable for work that will be published or replicated.

What if published results came from a gene therapy model and the plan is to use recombinant protein?

Redesign the exposure expectations before designing anything else. Viral-vector delivery produces continuous local expression in transduced tissue for months, whereas a recombinant protein produces a transient systemic exposure governed by rapid clearance. Our compound interaction and combination research page and the certificate reading guide both address how exposure model shapes interpretation.

What if two certificates from the same supplier show different purity values for the same product?

That is normal if the lot numbers differ, and alarming if they do not. Batch-to-batch variation in recombinant protein manufacture is expected, which is exactly why lot-specific documentation exists. Two different purity figures attached to one lot number indicates either a transcription error or a document that was not generated from an actual analytical run.

What is the unglamorous truth about myostatin pathway research?

Here is the honest answer: there is no published controlled human trial of administered Follistatin-344 protein, and anyone presenting the compound as a validated intervention is extrapolating from mouse gene therapy. The preclinical biology is genuinely interesting. The signalling mechanism is well characterised. But the gap between a transgene expressed continuously in murine muscle tissue and a lyophilised vial of recombinant protein is enormous, and the research community has mostly moved toward activin receptor fusion proteins and monoclonal antibodies precisely because follistatin's ligand promiscuity and rapid clearance make it an awkward tool. The anecdotal results page covers why self-reported accounts carry no evidentiary weight here.

How we researched this page

Everything above was compiled from peer-reviewed literature indexed on PubMed, with an inline link to the source record for every study claim. Where a figure could not be anchored to a verifiable publication, we described the finding qualitatively rather than inventing a number, which is why you will not find a single half-life value quoted on this page. Structural and gene-level facts, including splice variant nomenclature and chromosomal location, are drawn from standard protein and genome reference records.

We conducted no first-party laboratory testing on Follistatin-344 and make no analytical claims about any third-party preparation. We do not carry the compound. This page is a literature brief, not a product page.

Researchers working through the wider topic cluster can continue with the full literature review, the compound introduction, the body composition research summary, and our published certificates of analysis for the compounds we do supply.

The most useful thing to internalise about Follistatin-344 is that its greatest strength as a research tool is also its greatest limitation. A molecule that wraps itself around activins, myostatin, GDF-11, and several BMPs is a superb instrument for asking what happens when you silence an entire branch of TGF-beta signalling at once. It is a poor instrument for asking what any single ligand does on its own. Researchers who choose it deliberately for the former question tend to get clean, interpretable data. Those who reach for it expecting a selective myostatin switch spend the next six months trying to explain their off-target endpoints.